Acquisition Opportunity Courante Oncology was acquired by Harvest Integrated Research Organization (HiRO) in August 2023, signaling a strategic expansion and potential cross-sell opportunities within a larger CRO network for oncology clinical trial services.

Oncology Focus Specialization in oncology product development and trial management suggests a strong alignment with pharmaceutical and medical device clients pursuing cancer therapies, providing a targeted entry point for related CRO services and expanded scopes.

Growth Readiness Revenue tier of one to ten million and recent acquisition indicate growth ambitions; leverage this momentum to propose scalable trial management, quality assurance, and medical writing packages as the organization expands its global footprint.

Strategic Partnerships Given HiRO’s global CRO profile, there is potential to position Courante’s services as a complementary or bundled offering within a broader portfolio, creating opportunities for preferred vendor arrangements and larger multi-region trials.

Digital Footprint Current tech stack includes Snowplow, Cloudflare, and Microsoft 365 among others; tailor outreach around data-driven trial oversight, site monitoring efficiency, and robust cybersecurity as differentiators in highly regulated oncology studies.